Silence Therapeutics instate new COO
Silence Therapeutics, a company focused on developing medicines through the body’s natural mechanism of RNA interference, has appointed a new Chief Operating Officer. The position has been filled by Torsten Hoffman, who begins working in the role immediately.
Prior to Silence, Hoffman served as Chief Scientific Officer and Managing Director at Proteros for close to two years. He began his career at Roche and remained with the company for 15 years, beginning as Laboratory Head before moving up to become Head of Roche’s post-doctoral fellowship program.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented: “I am delighted that Torsten has joined Silence at this pivotal time for the company. As we continue to make progress with our new GalNAc-based platform, Torsten brings an experienced rigour to our operations with his knowledge from target selection through to clinical trials.”
He continued, “I have been impressed with his energy and the way that he has quickly formed a close working relationship with our Chief Scientific Officer, Dmitry Samarsky. As a consultant, he has already enabled us to drive efficiency through outsourcing certain activities and he will add further immediate benefits in the field of gene target selection and novel RNA therapeutics, helping to further differentiate Silence in delivering high quality medicines for better patients’ lives.”
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …